|
Volumn 51, Issue 7, 2015, Pages 447-452
|
Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015 - Washington, D.C., USA)
|
Author keywords
ANAVEX2 73; BI 409306; E 2609; Flutafuranol F 18; S 44858; Solanezumab; SUVN G3031; T 817MA; TTP 488
|
Indexed keywords
ACETYLCHOLINE;
AMPA RECEPTOR;
AMYLOID;
ANAVEX2 73;
AZELIRAGON;
BETA SECRETASE INHIBITOR;
BI 409306;
BIOLOGICAL MARKER;
DONEPEZIL;
E 2609;
FLUTAFURANOL;
FLUTAFURANOL F 18;
HISTAMINE;
HISTAMINE H3 RECEPTOR;
HISTAMINE H3 RECEPTOR ANTAGONIST;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR;
N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;
NEUROPROTECTIVE AGENT;
NEUROTRANSMITTER;
PF 4494700;
PHOSPHODIESTERASE 9A INHIBITOR;
PHOSPHODIESTERASE INHIBITOR;
PLACEBO;
S 44858;
SIGMA 1 OPIATE RECEPTOR;
SIGMA OPIATE RECEPTOR ANTAGONIST;
SOLANEZUMAB;
SUVN G 3031;
T 817MA;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
FLUORODEOXYGLUCOSE F 18;
MONOCLONAL ANTIBODY;
SIGMA OPIATE RECEPTOR;
SIGMA-1 RECEPTOR;
ALLOSTERISM;
ALZHEIMER DISEASE;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANXIETY DISORDER;
ASTHENOPIA;
BACKACHE;
BLURRED VISION;
BRAIN INFARCTION;
BRAIN INFARCTION SIZE;
CLINICAL DEMENTIA RATING;
COGNITION;
CONFERENCE PAPER;
CONTROLLED STUDY;
COUGHING;
DIARRHEA;
DISEASE SEVERITY;
DIZZINESS;
DRUG DOSE COMPARISON;
DRUG DOSE INCREASE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSGEUSIA;
DYSPEPSIA;
ELECTROENCEPHALOGRAM;
EPISTAXIS;
EVENT RELATED POTENTIAL;
EYE PAIN;
FATIGUE;
FLATULENCE;
GASTROINTESTINAL TOXICITY;
HEADACHE;
HUMAN;
IN VITRO STUDY;
IN VIVO STUDY;
INFECTION;
LIMB PAIN;
MACACA FASCICULARIS;
MALE;
MIDDLE CEREBRAL ARTERY OCCLUSION;
MOLECULARLY TARGETED THERAPY;
MOUSE;
MUSCLE SPASM;
NAUSEA;
NERVE CELL PLASTICITY;
NEUROLOGIC DISEASE;
NEUROPHARMACOLOGY;
NEUROPROTECTION;
NEUROTOXICITY;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PARESTHESIA;
PERIPHERAL EDEMA;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PHOTOPHOBIA;
POSITRON EMISSION TOMOGRAPHY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RASH;
RAT;
RECEPTOR OCCUPANCY;
REPEATED DRUG DOSE;
RHINITIS;
RHINOPHARYNGITIS;
SINGLE DRUG DOSE;
SLEEP WAKING CYCLE;
STRESS;
TREATMENT OUTCOME;
VISUAL IMPAIRMENT;
XEROSTOMIA;
ANIMAL;
ALZHEIMER DISEASE;
ANIMALS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
FLUORODEOXYGLUCOSE F18;
HUMANS;
POSITRON-EMISSION TOMOGRAPHY;
RECEPTORS, SIGMA;
|
EID: 84938693246
PISSN: 16993993
EISSN: 16994019
Source Type: Journal
DOI: 10.1358/dot.2015.51.7.2375989 Document Type: Conference Paper |
Times cited : (15)
|
References (0)
|